Companies: 10,795·Total market cap: $144.5T
Nkarta, Inc.

Nkarta, Inc.

NKTXNASDAQHealthcare● Active
$2.40
$-0.11(-4.38%)
Market Cap$171708859
P/E Ratio
52W High$3.65
52W Low$1.63

Nkarta, Inc. (NKTX) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

nktx · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Nkarta, Inc. (NKTX) measures how much investors pay for each dollar of the company's trailing earnings. NKTX's current PE ratio of N/A is calculated by dividing its stock price of $2.40 by its TTM earnings per share of -$1.35.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.37
Based on 3 analysts
EPS (TTM)
-$1.35
TTM · diluted EPS
PEG Ratio
-0.15
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nkarta, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Nkarta, Inc.
Nkarta, Inc.You
NKTX
$172MN/A-$1.35
Alector, Inc.
Alector, Inc.
ALEC
$182MN/A-$1.39
Applied Therapeutics, Inc.
Applied Therapeutics, Inc.
APLT
$15MN/A-$0.76
Cybin Inc.
Cybin Inc.
CYBN
$413MN/A-$0.61
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc.
ELTX
$259MN/A-$2.58
Fate Therapeutics, Inc.
Fate Therapeutics, Inc.
FATE
$223MN/A-$1.15
Forte Biosciences, Inc.
Forte Biosciences, Inc.
FBRX
$218MN/A-$0.47

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.41
2024-12-31
FY2024
$-1.60
2023-12-31
FY2023
$-2.40
2022-12-31
FY2022
$-2.61
2021-12-31
FY2021
$-2.62
2020-12-31
FY2020
$-2.87
2019-12-31
FY2019
$-2.35
2018-12-31
FY2018
$-0.01

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Nkarta, Inc. (NKTX) measures how much investors pay for each dollar of the company's trailing earnings. NKTX's current PE ratio of N/A is calculated by dividing its stock price of $2.40 by its TTM earnings per share of -$1.35.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.40 ÷ -$1.35 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

NKTX pe ratio · 6 questions

NKTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.40 and TTM EPS of -$1.35. Data sourced from Financial Modeling Prep via NKTX's SEC 10-K and 10-Q filings.

NKTX PE ratioWhat is NKTX PE ratioCurrent PE ratio of NKTXNKTX PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nkarta, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09